Booster doses of JnJ COVID vaccine recommended by USFDA

Published On 2021-10-17 04:00 GMT | Update On 2021-10-17 04:00 GMT

Washington: A US Food and Drug Administration (FDA) advisory committee has voted to recommend authorising a booster dose of the Johnson & Johnson's Covid-19 vaccine.

The agency's Vaccines and Related Biological Products Advisory Committee voted unanimously on Friday, 19-0, to recommend authorisation of the second dose as early as two months after the primary shot for anyone aged 18 and older, reports Xinhua news agency.

The same committee on Thursday recommended Moderna booster shots to people aged 65 and older and other high-risk adults, in line with guidelines for Pfizer's vaccine.

It allowed Moderna to supply third doses of its vaccine to people who had their second doses at least six months ago and are over 65, have underlying health conditions, or whose jobs put them at high risk of contracting severe Covid-19.

All 19 voting members voted in favour.

Earlier this month, the US regulators had authorised Covid booster shots of Pfizer and BioNTech's.

However, unlike for Pfizer, Moderna has been recommended for only half-dose booster to bolster protection against the virus.

Just under 188 million people in the US have now been fully vaccinated, according to the CDC.

Around 9 million of those have also received booster doses, data shows.

More people are now getting booster doses than receiving their first shots, it added.

Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Booster doses of JnJ COVID vaccine recommended by USFDA

Similar News

Russia's Enteromix Cancer Vaccine Shows 100% Success in Trial, Awaits Final Nod for Public Use

Mankind Pharma wins CDSCO nod to start Phase 1 trials of Autoimmune drug candidate

India seeks to boost drug exports to semi regulated markets in Africa, Latin America, Southeast Asia

Jubilant Ingrevia appoints Sonia Dharap as Vice President - Sales, Business Development (US)

EMA warns of sharp rise in illegal medicines sold in EU

Indegene opens new center in Pune, boosts India presence

Indian medical devices share increased from 10% to 30% of domestic requirements in last 5 years: DoP Secretary

AstraZeneca announces Rs 176 crore investments in India to expand Chennai GITC